

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_85501
Title of the Manuscript:	MONOCLONAL ANTIBODIES: USAGE IN THE TREATMENT OF COVID-19 INFECTION
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	"Matherial and method" includes also " Discussions"	Noted
<u>Minor</u> REVISION comments	In paragraph 2.6. beside the month (February, September) the year should also be mentioned In table 1 pneumonia is cited as side effect of Sotrovimab – I would comment this as a bias Infants are mentioned in paragraph 2.3. (high-risk condition) and also in paragraph 2.6. but there are no comments on the specific role and current recommendations of using these drugs in children between 1 an 12 years of age, and infants	Revised
<u>Optional/General</u> comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	